Final answer:
Clozapine is the drug subject to the "No Blood, No Drug" REMS program, which requires regular neutrophil count monitoring before the drug is dispensed due to the risk of neutropenia.
Step-by-step explanation:
The drug that requires the "No Blood, No Drug" Risk Evaluation and Mitigation Strategy (REMS) program is Clozapine. This program is a strict safety protocol due to the serious risk of neutropenia (an abnormally low number of neutrophils) associated with Clozapine. Neutrophils are a type of white blood cell critical for fighting infections. The "No Blood, No Drug" REMS ensures that before a patient receives Clozapine, their absolute neutrophil count (ANC) is monitored regularly. Prescribers must enroll in the REMS program, and pharmacies also have to be certified to dispense the medication, ensuring that the necessary blood testing is conducted before Clozapine is dispensed to the patient. This relationship between blood test results and medication dispensing is what gives the REMS its name, "No Blood, No Drug."